RxDoctor Payments Data

Blair Lewis, MD

Gastroenterology · New York, NYNPI 1689765521

Payments from drug & device makers

$61,329in general payments, 2019–2025

Across 182 payments — averaging $336.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$26K
  • AbbVie$15K
  • Sanofi US Services Inc.$8K
  • Takeda Pharmaceuticals U.S.A., Inc.$7K
  • Pfizer$5K
  • Bristol Myers Squibb$282
  • plus $998 from 12 others
$1,875in research payments, 2019–2025

Across 5 payments — averaging $375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Consulting fees$18,25088%
  • Food & beverage$2,33911%
  • Other$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,329 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$147,639
Medicare patients
683
Services billed
1,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$148,698
LinzessLinaclotide55$39,993
SutabSod Sulf/Pot Chloride/Mag Sulf125$20,186
Pantoprazole Sodium440$6,605
Dexlansoprazole DrDexlansoprazole21$5,600
Mesalamine25$4,356
Esomeprazole Magnesium38$3,822
ClenpiqSod Picosulf/Mag Ox/Citric Ac17$2,946
Famotidine124$2,298
Budesonide DrBudesonide17$1,147
Lactulose34$1,124
Amitriptyline Hcl93$1,122
Mirtazapine41$918
Omeprazole54$833
Dicyclomine Hcl25$584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$14,806$39,99355 claims
Ferring Pharmaceuticals Inc.Clenpiq$210$2,94617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →